The ras genes are members of a highly conserved family of vertebrate genes first detected as the oncogenes of Harvey and Kirsten sarcoma viruses (1). They encode immunologically cross-reactive, guanine nucleotide binding proteins of -21,000 daltons (2). There are at least three human ras genes, H-, K-, and N-ras, which encode four distinct ras peptides of 188 or 189 amino acids, identical in sequence for the first 86 positions (3-5). Mutated ras genes have been detected in some human tumor cells by the ability of tumor cell DNA to induce tumorigenic transformation in NIH 3T3 cells upon DNA-mediated gene transfer. To date, many activating mutations of ras genes from human tumor cells have been analyzed and they all specify amino acid substitutions at position 12 or 61 of the encoded protein (3-11). To determine whether other mutations of the ras genes could also activate the transforming potential of the wild-type normal genes, we tested the transforming capacity of randomly mutagenized wild-type H-ras genes.
ABSTRACT
Some tumor cells contain mutant ras genes that are capable of transforming NIH 3T3 cells. Those genes that have been analyzed arise from the wild-type, non-transforming ras genes by mutations producing single amino acid substitutions at position 12 or 61 of the encoded protein. We have performed random bisulfite-induced mutagenesis on the cloned wild-type human H-ras gene to find if mutations at other positions can activate the transforming potential of that gene. Most mutations are not activating, but mutations that specify single amino acid substitutions at position 12, 13, 59, or 63 of the encoded protein do activate the transforming potential of the H-ras gene. Some, but not all, mutant ras proteins show an altered electrophoretic mobility in NaDodSO4/polyacrylamide gels.
The ras genes are members of a highly conserved family of vertebrate genes first detected as the oncogenes of Harvey and Kirsten sarcoma viruses (1) . They encode immunologically cross-reactive, guanine nucleotide binding proteins of -21,000 daltons (2) . There are at least three human ras genes, H-, K-, and N-ras, which encode four distinct ras peptides of 188 or 189 amino acids, identical in sequence for the first 86 positions (3) (4) (5) . Mutated ras genes have been detected in some human tumor cells by the ability of tumor cell DNA to induce tumorigenic transformation in NIH 3T3 cells upon DNA-mediated gene transfer. To date, many activating mutations of ras genes from human tumor cells have been analyzed and they all specify amino acid substitutions at position 12 or 61 of the encoded protein (3) (4) (5) (6) (7) (8) (9) (10) (11) . To determine whether other mutations of the ras genes could also activate the transforming potential of the wild-type normal genes, we tested the transforming capacity of randomly mutagenized wild-type H-ras genes.
MATERIALS AND METHODS
Cells, Transfections, and Immunoprecipitations. NIH 3T3 cells were cultured and transfected as described (12) . Morphologically altered foci were scored 18 days after DNA transfer. Escherichia coli strains were MM294 (r-m+, rec+) for routine plasmid growths and BD1528 (ung-) (the gift of D. Shortle) was used only for transfection of DNA after bisulfite mutagenesis. E. coli transfections were performed as described (13) . Cell labeling and immunoprecipitations were performed as described (14) .
Plasmid DNAs and Sequencing. The plasmid pT24 contained the transforming H-ras gene of T24 bladder carcinoma cells, encoding valine in position 12 (8, 15) . The plasmid pP3 contained the wild-type human H-ras gene, encoding glycine in position 12, cloned initially from human placenta (8) . The plasmid pTPT differs from pT24 only in containing the 242-base-pair (bp) Mst II/Xba I fragment of the wild-type H-ras gene contained in pP3. Its map is shown in Fig. 1 . It therefore encodes glycine in position 12 and a normal H-ras protein. The plasmid EMS9 differs from pT24 in that it lacks any intron after the first coding exon. It was constructed by using the plasmids RC3 and RC6 containing cDNAs of the Hras transcript (15) . The protein it encodes also contains valine in position 12. The plasmid EMSH3 differs from EMS9 in that it contains the 34-bp Hae II/Pvu II fragment of the viral Harvey ras gene (16) , cloned into the corresponding Hae II/Pvu II site of plasmid EMS9. It therefore encodes arginine in position 12. Clones of bisulfite-mutagenized pTPT were initially grown in ung-BD1528 and then transfected into MM294 for large-scale growth. DNA restriction endonuclease fragments from the mutagenized regions were subcloned into the original pTPT plasmid and grown in MM294. Plasmid DNAs for DNA sequencing or transfection of animal cells was prepared by either of two methods. Large-scale individual plasmid DNAs were prepared from one-liter cultures of MM294 by the method of detergent lysis and CsCl/ethidium bromide banding (17) . DNAs from ung-E. coli containing mutagenized plasmids were made on 5-ml saturated cultures by previously published methods (18) . DNA sequencing was performed according to Maxam and Gilbert (19) by using the strategy published previously (15) .
Sodium Bisulfite Mutagenesis of Doubly Gapped, Circular pTPT Molecules. For mutagenesis of the ras gene coding regions, supercoiled pTPT DNA (20 ,ug in a 200-,ul reaction volume) was digested to completion with pairs of restriction endonucleases. To mutagenize the region encoding amino acids 1-37, EcoRI and Xba I were used. To mutagenize the region encoding amino acids 38-110, Xba I and Nco I were used (see Fig. 1 ). At the end of the incubation, 20 tTo whom reprint requests should be addressed.
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mentary DNA strands were electroeluted together in TNE buffer for 12 hr at 80 V. To the resulting solution (-20 ml), 2 ml of 1 M Tris-HCl (pH 7.5), 2 ml of 5 M NaCl, and 0.2 ml of 0.25 M EDTA were added, and any insoluble material was removed by centrifugation in 50-ml Falcon tubes at 1800 x g for 15 min. Circular, partially single-stranded plasmid DNA was formed by immersion of the 50-ml Falcon tubes containing the above described solution in a 1-liter bath that was allowed to warm up to 760C on a heating plate. After 10 min at this temperature, the plate was switched off and the solution was allowed to cool slowly to room temperature. After addition of 200 Ag of tRNA and 2 vol of ethanol, the solution was kept for 12 hr at -80'C and then centrifuged at 25,000 rpm in siliconized polyallomer tubes for 30 min at 40C in a SW 27 rotor. The plasmid DNA pellet was resuspended in 200 pd of 1.5 mM sodium citrate, pH 7.0/15 mM NaCl and treated with 3 M bisulfite for 10 min at 370C as described by Shortle and Nathans (20) . After ethanol precipitation, mutagenized and gapped DNA was dissolved in 50 kd of 10 mM Tris HCl, pH 7.5/1 mM EDTA. ung-E. coli was then transformed by the gapped and mutagenized DNA. We obtained from 200 to 2000 ampicillin-resistant colonies per ug of DNA. Ampicillin-resistant colonies were handled as described in the text. The extent of bisulfite mutagenesis was monitored both by the loss of restriction endonuclease sites and DNA sequence analysis of randomly selected mutagenized plasmids. By this method we detected no unmutagenized plasmids.
Oligonucleotide Screening of Mutants. Oligonucleotides were synthesized by the modified phosphate triester method (21) using a BIOSEARCH SAM DNA synthesizer and were purified by electrophoresis in a 20% acrylamide/8 M urea gel. Oligonucleotide screening of bacterial colonies containing the mutant plasmids was done as described by Wallace et al. (22) . RESULTS Sodium bisulfite treatment of plasmid DNA containing a single-stranded gap will induce the chemical conversion of deoxycytidine into deoxyuridine residues preferentially in the single-stranded region (20, 23) . The extent of this reaction can be controlled by time and bisulfite concentration. After treatment, introduction of the plasmid DNA into ung-E. coli, lacking deoxyuridine N-glycosidase, results in gap repair and replication with the final result that some C-G pairs are converted to T-A pairs. We treated in this manner a clone of the human H-ras gene that encodes a normal ras protein in order to introduce random mutations in coding regions. Single-stranded gaps were introduced as shown in Fig. 1 . Two regions were mutagenized separately: region I, 2.3 kilobase pairs (kbp) spanning EcoRI to Xba I; and region II, 509 bp spanning Xba I to Nco I. Both coding and noncoding strands were mutagenized. As a result, 25 codons in region I, encoding the first 37 amino acid positions, and 51 codons in region II, encoding amino acid positions 38-110, could be mutagenized, including the 12th but not the 61st codons.
Gapped plasmids were treated so that on average 1 deoxycytidine residue per 30 was altered. After transformation of ung E. coli, several hundred colonies of ampicillin-resistant E. coli were individually picked and grouped into pools of 10 colonies each. Plasmid DNA was prepared from each pool of 10 and tested for the ability to induce the typical foci of morphologically altered NIH 3T3 murine fibroblasts that we associate with mutated ras genes that have transforming capacity. Plasmid DNAs were then individually tested from pools that were positive. Since the substitution of threonine for alanine in position 59 is also found in the ras genes of the Harvey and Kirsten sarcoma viruses, we were interested in determining if this mutation alone sufficed to activate the transforming potential of ras genes. To this end, we synthesized an oligonucleotide, T-G-G-C-C-G-G-T-G-G-T-A-T-C-C, which is complementary to the sequence of the mutant encoding a threonine substitution, and used this as a probe to isolate threonine substitution mutants among a larger population of plasmids mutagenized in region II. Eight were isolated. Including the previous threonine mutant, at least four of nine mutants were unique, as judged by the pattern of loss of restriction endonuclease sites in the mutagenized region. Seven of the eight new mutants had transforming activity when tested on NIH 3T3 cells. One of these was sequenced, and it too contained multiple amino acid substitutions: arginine for lysine at position 42, asparagine for aspartic acid at position 47, and methionine for valine at position 81, in addition to threonine for alanine at position 59. However, since seven of eight randomly picked threonine substitution mutants efficiently transformed NIH 3T3 cells and since most mutations do not activate the ras gene, we conclude that it is highly probable that substitution of threonine for alanine in position 59 is sufficient to activate the transforming potential of the ras genes.
We measured the transforming capacity of our chimeric genes in NIH 3T3 focus assays. For comparison, we utilized the pT24 plasmid specifying valine for glycine in position 12. We also included in this survey an H-ras gene we constructed specifying another single amino acid substitution at position 12: arginine for glycine. This was made by recombining in vitro the wild-type human H-ras gene with the Harvey sarcoma virus ras gene that encodes arginine at position 12 (see Materials and Methods). The efficiency of transformation of the various mutants varied considerably. The differences we observed between mutants were reproducibly obtained in independent experiments but may not be biologically significant since we have not excluded the existence of additional mutations within introns. (6) , as does the K-ras protein of Calu-1 lung carcinoma cells (24) , which contains a cysteine substitution at position 12 (4, 5) . On the other hand, the N-ras protein of SK-N-SH neuroblastoma cells, which contains a lysine substitution in position 61 (3), runs more rapidly than expected (25) . To explore whether this is a general property, we examined the electrophoretic mobility of our mutant proteins in NaDodSO4/ polyacrylamide gels (see Fig. 2 Both the Harvey and Kirsten sarcoma viral ras proteins have a threonine residue at position 59 in place of the alanine residue encoded by wild-type ras genes (16, 26) . This residue is the site of phosphorylation of the viral proteins (27) . In contrast, the wild-type H-ras protein is phosphorylated only at very low levels at one or more seine residues (2) . We have found that all of the mutant ras proteins containing threonine at position 59 are phosphorylated efficiently in (14) . Cell extracts were immunoprecipitated with anti-ras monoclonal antibody Y13-238 (14) . Immunoprecipitates (14) were electrophoresed through a 4% polyacrylamide stacking gel and a 30-cm-long 12% polyacrylamide resolving gel as described (32) vivo (data not shown). It is highly probable that this modification occurs at threonine 59 and results from autophosphorylation using GTP as substrate, as has been shown for the viral ras proteins (2, 27, 28) . We conclude that transforming mutations affecting residue 12 are not required and that threonine 59 alone suffices for efficient phosphorylation of the H-ras protein.
DISCUSSION
Transforming genes have been found in RNA tumor viruses and in tumor cells. In general, they derive from normal cellular genes by a variety of complex processes: translocation, transduction, deletion, fusion, and point mutation (29) . The clearest examples are the transforming ras genes, which differ from normal ras genes by a single point mutation resulting in a single amino acid substitution of the encoded protein (3) (4) (5) (6) (7) (8) (9) (10) (11) .
In our present study we have utilized random bisulfite mutagenesis, a generally applicable procedure, for finding point mutations that can activate the transforming potential of a normal gene. We have not conducted an exhaustive study. We have not, for example, mutagenized the 3' one-third of the H-ras gene, and we have probably not assessed all of the possible bisulfite-inducible mutations even in the regions we did mutagenize. There are intrinsic limits to the bisulfite mutagenesis: not all positions can be mutated and of those that can, only a circumscribed set of nucleotide changes can result. Moreover, recent work from our laboratory (unpublished) indicates that not all cytosine residues in a singlestranded region are equally likely to be modified by bisulfite treatment. Nevertheless, the rate-limiting step in endeavors Biochemistry: Fasano et aL W 0 of this kind is not the number and variety of mutants but their screening and analysis. For this reason, a method of mutagenesis that always introduced just single random mutations in the mutagenized DNA would be preferable.
We have found an interesting set of new transforming mutants. Not only can any of several mutations of the 12th and 61st codons activate the transforming potential of the ras genes, a conclusion that comes from previous studies, but also mutations of the 13th and 63rd codons can, and, very probably, mutations of the 59th codon as well. Tabin et al. (6) first noted that ras p21 with valine substituting glycine in position 12 had altered electrophoretic mobility in NaDod-S04/polyacrylamide gels. Computer predictions have indicated that any amino acid substitution for glycine in position 12 could drastically alter ras p21 conformation by extending the protein from its normally compact form (30) , consistent with the observed shifts in electrophoretic mobility of mutant p2is. Our data indicate that some, but not all, amino acid substitutions at positions 12 and 13 that have drastic effects on ras p21 function can significantly alter protein mobility in NaDodSO4/polyacrylamide gels. Our data also indicate that amino acid substitutions in the region about positions 59-63 also greatly alter p21 mobility. These observations are consistent with the idea that the amino acid substitutions that activate ras p21 do so by disrupting protein structure, thereby disrupting some critical protein function.
We argue that the region about positions 59-63 neighbors the GTP binding site of the ras proteins, since when threonine is encoded in position 59, it is a site for autophosphorylation by GTP (27) . Others have argued that region about amino acids 12 and 13 may neighbor the ras GTP binding site, since this region has amino acid homology to known nucleotide binding proteins (31 (16, 26 ).
Yet, the present study indicates that any one of these mutations is sufficient to strongly activate ras. We can offer no simple explanation for this at present.
